Evidence on the role of NF-κB signaling pathway in inflammation associated respiratory diseases, e.g., asthma and COPD, is convincing, therefore an impact on this pathway can be a gate opener for the use as therapeutic substance within these diseases (Edwards et al., 2009). This evidence concerns the gene NFKB1 and chronic obstructive pulmonary disease.